2 recruiting, 1 active not recruiting, 1 completed, 1 terminated. 6 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 6 | Recruiting 2, Active not recruiting 1, Completed 1, Terminated 1, Unknown 1 |
Follow Calcium levofolinate: new trials by email Literature Review of Calcium levofolinate trials Research Report on Calcium levofolinate
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study of BL-M07D1 Versus Physician's Choice of Chemotherapy in Patients With HER2-expressing Locally Advanced or Metastatic Biliary Tract Cancer After Platinum-containing Chemotherapy Failure BL-M07D1, Oxaliplatin, Calcium levofolinate - Biliary Tract Cancer | Phase 3 | Recruiting | Sichuan Baili Pharmaceutical Co., Ltd. | 398 | 2026-07-07 | 2026-07-24 |
| A Study Comparing BL-B01D1 With Treatment of Physician's Choice in Patients With Locally Advanced or Metastatic Biliary Tract Cancer After Failure of Platinum-based Chemotherapy(PANKU-BTC01) BL-B01D1, Oxaliplatin, Calcium levofolinate - Biliary Tract Cancer | Phase 3 | Recruiting | Sichuan Baili Pharmaceutical Co., Ltd. | 538 | 2026-06-29 | 2026-07-24 |
| Efficacy and Safety of Pembrolizumab (MK-3475) Plus Lenvatinib (E7080/MK-7902) Plus Chemotherapy in Participants With Metastatic Esophageal Carcinoma (MK-7902-014/E7080-G000-320/LEAP-014). Pembrolizumab, Lenvatinib, Cisplatin - Metastatic Esophageal Squamous Cell Carcinoma | Phase 3 | Terminated | Merck Sharp & Dohme LLC | 863 | 2021-07-28 | 2026-08-21 |
| Study in mCRC Patients RAS/BRAF wt Tissue and RAS Mutated LIquid BIopsy to Compare FOLFIRI Plus CetuxiMAb or BevacizumaB Bevacizumab, Cetuximab, 5-FU - Colorectal Cancer, Metastatic Colorectal Cancer | Phase 3 | Active not recruiting | Azienda USL Reggio Emilia - IRCCS | 280 | 2021-04-30 | 2026-07-24 |
| Study of Pembrolizumab (MK-3475) Versus Placebo in Participants With Esophageal Carcinoma Who Are Receiving Chemotherapy and Radiation Therapy (MK-3475-975/KEYNOTE-975) pembrolizumab, placebo, cisplatin - Esophageal Squamous Cell Carcinoma (ESCC), Gastroesophageal Junction Carcinoma (GEJC) | Phase 3 | Completed | Merck Sharp & Dohme LLC | 703 | 2020-02-28 | 2026-10-30 |
| Adjuvant Chemotherapy Combined With Huaier Granule for Treating High-risk Stage II, Stage III Colorectal Cancer Huaier Granule, Oxaliplatin, Calcium folinate - Colorectal Cancer | Phase 3 | Unknown | Sixth Affiliated Hospital, Sun Yat-sen University | 230 | 2016-06-01 | 2016-06-08 |
Biliary Tract Neoplasms (2) · Colorectal Neoplasms (2) · Esophageal Squamous Cell Carcinoma (2) · Parkinson Disease 4, Autosomal Dominant Lewy Body (2) · Adenocarcinoma Of Esophagus (1) · Neoplasm Metastasis (1)
Merck Sharp & Dohme LLC (2) · Sichuan Baili Pharmaceutical Co., Ltd. (2) · Azienda USL Reggio Emilia - IRCCS (1) · Sixth Affiliated Hospital, Sun Yat-sen University (1)
China (5) · Italy (3) · Argentina (2) · Canada (2) · Chile (2) · Denmark (2) · France (2) · Guatemala (2) · Hong Kong (2) · Hungary (2) · Japan (2) · Romania (2) · Russia (2) · South Korea (2) · Taiwan (2)
Erika Gervasi (1) · Irene De Simone (1) · Xiaojian Wu, Ph.D. (1)
PMID 20718753, PMID 22895629, PMID 23599758, PMID 25077927, PMID 33533655, PMID 38695479
2019 (1)